TrialBone marrow transplantation2021

Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.

Xiaowen Tang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.